Loading…
CONMED Corporation is projected to rise to $56.16 by 2027, a +21% move from its current price of $46.30. CNMD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $44.87 | $46.33 | $47.84 | +0.06% |
| Aug 3 | $44.31 | $46.36 | $48.50 | +0.13% |
| Aug 4 | $43.89 | $46.39 | $49.03 | +0.19% |
| Aug 5 | $43.54 | $46.42 | $49.48 | +0.25% |
| Aug 6 | $43.24 | $46.45 | $49.89 | +0.31% |
| Aug 7 | $42.97 | $46.47 | $50.26 | +0.38% |
| Aug 8 | $42.73 | $46.50 | $50.61 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $42.73 | $46.50 | $50.61 | +0.44% |
| Week 2 | $41.44 | $46.71 | $52.65 | +0.88% |
| Week 3 | $40.52 | $46.91 | $54.32 | +1.33% |
| Week 4 | $39.78 | $47.12 | $55.81 | +1.77% |
| Week 5 | $39.17 | $47.33 | $57.19 | +2.22% |
| Week 6 | $38.63 | $47.54 | $58.49 | +2.67% |
| Week 7 | $38.17 | $47.75 | $59.73 | +3.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CONMED Corporation is a medical technology company that develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products that enable minimally invasive sports medicine surgeries. It markets products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors.
The company was incorporated in 1970 and is headquartered in Largo, Florida. Its broader portfolio includes powered resection instruments, fluid management and visualization systems, general surgery products under the AirSeal brand, smoke removal devices under the Buffalo Filter brand, endomechanical products, and endoscopic technologies for gastroenterology procedures and related patient monitoring products. These lines collectively position CONMED within the healthcare devices sector.
CONMED operates across multiple surgical disciplines, including orthopedic, general, endoscopic, and cardiothoracic procedures, serving hospitals and centers through a direct and distributor-based model.
CNMD is a medical technology company focused on surgical devices and equipment, with a current price of $46.98, a market capitalization of $1.41B, and a market rank of 2147. The stock shows a bullish long-run outlook in the forecast series, with near-term momentum and a clear path of potential appreciation over the coming years.
Near term, the stock sits near the upper end of a current trading range, while the 30-day range provides context for volatility and downside risk. The forecast implies a gradual price increase from 2026 onward, with higher average prices expected in successive years and a long-run bullish trajectory through 2050.
A major floor 40.6% below — a decisive break under it would weaken the trend.
The nearest floor, 29.7% below — buyers have tended to step in here.
Price is pressing into resistance (1.5% away) — a breakout level to watch.
A major ceiling 21.8% above — clearing it would confirm fresh momentum.
Key CNMD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CNMD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $44.85 | Buy | $45.07 | Buy |
| MA 10 | $43.55 | Buy | $43.83 | Buy |
| MA 20 | $41.44 | Buy | $41.82 | Buy |
| MA 50 | $37.42 | Buy | $39.10 | Buy |
| MA 100 | $37.13 | Buy | $38.71 | Buy |
| MA 200 | $39.91 | Buy | $41.23 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.36 | Neutral |
| Stoch RSI (14) | 56.15 | Neutral |
| CCI (20) | 110.73 | Buy |
| Williams %R (14) | -11.91 | Info |
| MACD (12,26,9) | 0.33 | Buy |
| ROC (12) | 8.20 | Buy |
| Bollinger %B (20,2) | 0.83 | Neutral |
| Stochastic %K (14) | 88.09 | Sell |
| TRIX (15) | 0.85 | Buy |
| Awesome (5,34) | 6.53 | Buy |
| Ultimate (7,14,28) | 69.24 | Neutral |
| Momentum (10) | 3.10 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 46.19 | Buy |
| ADX (14) | 23.55 | Buy |
| ATR (14) | 1.29 | Info |
The 30-day technical picture shows bullish sentiment with RSI at 70. The 50-day simple moving average sits at $37.22, while the 200-day simple moving average is at $39.89, indicating potential upside as prices move back toward or above these levels.
Support is cited at $32.11 and resistance at $46.98, marking a defined trading band. The 30-day range runs from a low of $37.83 to a high of $58.35, illustrating the recent volatility and the scope for profitability if price momentum persists.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $32.11 | $46.30 | $60.22 | 0% | Neutral | |
| $44.09 | $56.16 | $76.05 | +21% | Bullish | |
| $43.98 | $57.94 | $81.91 | +25% | Bullish | |
| $46.02 | $62.34 | $91.11 | +35% | Bullish | |
| $50.50 | $70.13 | $105.39 | +51% | Bullish | |
| $52.81 | $75.02 | $115.50 | +62% | Bullish | |
| $66.36 | $96.28 | $151.45 | +108% | Bullish | |
| $76.34 | $112.98 | $181.23 | +144% | Bullish | |
| $76.70 | $115.68 | $188.92 | +150% | Bullish | |
| $77.06 | $118.36 | $196.52 | +156% | Bullish | |
| $119.64 | $199.69 | $355.28 | +331% | Bullish | |
| $166.58 | $321.89 | $632.76 | +595% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $32.11 | $46.30 | $55.46 | +0.00% |
| September 2026 | $39.53 | $47.00 | $57.65 | +1.52% |
| October 2026 | $40.90 | $49.03 | $60.88 | +4.31% |
| November 2026 | $40.37 | $48.71 | $61.09 | -0.64% |
| December 2026 | $39.21 | $47.59 | $60.22 | -2.30% |
Click any year to see its month-by-month CNMD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CNMD is projected to trade between $32.11 and $60.22, averaging $46.30 — a potential gain of 0% from today's $46.30. A consolidation phase looks the most probable path here.
CONMED Corporation's 2027 outlook centres on $56.16, within a $44.09 to $76.05 range. That is up +21% on the projected 2026 average. That marks a +21% change versus current levels. Momentum favours further upside here.
By 2028, CNMD could reach as high as $81.91, with a base case around $57.94 and support toward $43.98 — roughly +25% from $46.30. Buyers look set to stay in control over this stretch.
Expect CNMD to range from $46.02 to $91.11 through 2029. The $62.34 average target implies a +35% move from current prices. That is up +8% on the projected 2028 average. Momentum favours further upside here.
The CNMD price prediction for 2030 points to an average of $70.13 (low $50.50, high $105.39) — a potential gain of +51% on today's $46.30. Buyers look set to stay in control over this stretch.
In 2031, CNMD is projected to trade between $52.81 and $115.50, averaging $75.02 — a potential gain of +62% from today's $46.30. That is up +7% on the projected 2030 average. Momentum favours further upside here.
CONMED Corporation's 2032 outlook centres on $96.28, within a $66.36 to $151.45 range. That is up +28% on the projected 2031 average. That marks a +108% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CNMD could reach as high as $181.23, with a base case around $112.98 and support toward $76.34 — roughly +144% from $46.30. Momentum favours further upside here.
Expect CNMD to range from $76.70 to $188.92 through 2034. The $115.68 average target implies a +150% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CNMD price prediction for 2035 points to an average of $118.36 (low $77.06, high $196.52) — a potential gain of +156% on today's $46.30. Momentum favours further upside here.
In 2040, CNMD is projected to trade between $119.64 and $355.28, averaging $199.69 — a potential gain of +331% from today's $46.30. That is up +69% on the projected 2035 average. Buyers look set to stay in control over this stretch.
CONMED Corporation's 2050 outlook centres on $321.89, within a $166.58 to $632.76 range. That is up +61% on the projected 2040 average. That marks a +595% change versus current levels. Momentum favours further upside here.
Investing $1,000 in CNMD today (≈ 21.598272 CNMD) could be worth
$6,952.34
+$5,952.34 (+595%) by 2050 · US Dollar
Based on the average projected CNMD price of $321.89 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CNMDwould be worth at today's price.
$1,000 invested in CNMD on Jul 31, 2025 (≈ 19.550342 CNMD) would be worth
$905.18
-$94.82 (-9.5%) today · 0.91× · US Dollar
Based on a CNMD entry price of $51.15 vs. today's $46.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $42.68 | $1,084.82 | +8.5% |
| 1 month ago | $32.76 | $1,413.31 | +41.3% |
| 3 months ago | $36.8 | $1,258.15 | +25.8% |
| 6 months ago | $39.21 | $1,180.82 | +18.1% |
| 1 year ago | $51.15 | $905.18 | -9.5% |
| All time (5.0y) ago | $136.01 | $340.42 | -66.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CNMD forecast.
Our base-case forecast reaches $93.00 around 2032.
Implied market cap at $93.00: $2.79B
The multi-year forecast portrays a bullish trajectory with rising average prices and meaningful upside across decades. In 2026, the average forecast is $46.98 with a range from $32.11 to $61.29 and a 0 ROI, signaling a neutral sentiment for that year. By 2027, the average progresses to $57.35 with a range from $44.88 to $77.97, and ROI of 22.1, signaling a bullish shift.
The 2028 and 2029 forecasts show continued gains, with averages of $59.20 and $63.94 and ROI of 26 and 36.1, respectively, maintaining a bullish outlook. By 2030, the average reaches $72.38 with a range of $51.82 to $109.46 and ROI of 54.1, sustaining bullish sentiment through the decade.
Looking further out, 2031–2035 show stronger upside with 2031 average $77.70, 2032 $100.55, 2033 $118.31, 2034 $120.76, and 2035 $123.80, all bearing bullish sentiment and rising ROI up to 163.5. The 2040 forecast increases dramatically to an average of $211.25 with a max of $379.47 and ROI of 349.7, while 2050 envisions an average of $342.31, a max of $680.51, and ROI of 628.6, maintaining bullish sentiment. These figures illustrate a long-run path of valuation expansion, though they are not guarantees and carry inherent investment risk.
Tap a question to reveal the answer.
In 2030, the forecasted average price is $72.38 with a min of $51.82 and a max of $109.46, and ROI of 54.1, with bullish sentiment.
The forecast shows bullish sentiment from 2027 onward, with rising averages and ROI from 22.1 in 2027 to 628.6 in 2050, though 2026 is neutral with ROI 0.
Yes. The 2030 max is $109.46, and later years show higher maximums such as $159.33 in 2032 and $191.25 in 2033, with even higher levels in 2040 and 2050.
The current price is $46.98. The 30-day range is from $37.83 to $58.35.
For 2026, the average price is $46.98 with a range from $32.11 to $61.29 and ROI of 0, with neutral sentiment.
CONMED Corporation Community Discussion
0Share your CONMED Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.